Indivior PLC (IZQVF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Drug Manufacturers - Specialty & Generic industria. La empresa tiene su sede en North Chesterfield, VA, United States. El CEO actual es Mark Crossley.
IZQVF tiene fecha de IPO 2014-12-26, 1,000 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $2.89B.
Indivior PLC is a specialty pharmaceutical company that develops, manufactures, and markets buprenorphine-based prescription medications for treating opioid dependence and related disorders. The company's primary products include SUBLOCADE, an injectable formulation, and SUBOXONE, available in sublingual film and tablet forms, alongside legacy medications such as Temgesic and Buprenex. With operations spanning approximately 40 countries worldwide, Indivior focuses on addressing opioid use disorder, addiction, and co-occurring conditions through its product pipeline. Headquartered in North Chesterfield, Virginia, the company was established in 2014 and maintains research collaborations to advance its therapeutic offerings.
